This study aims to evaluate the impact of two newly developed formulas compared to a commercially available DSNF on glucose–insulin homeostasis, serum GLP-1, serum free fatty acids and serum triglycerides (TG) in obese T2DM patients. Here, INS is linked to type 2 diabetes mellitus.